The research report on the economic impact of ramipril by Carroll et al. 1 is important in that it addresses the need to assess and report economic analyses of major clinical trials with significant findings. The study specified that savings due to decreased hospitalizations from cardiovascular events outweigh costs associated with ramipril, an angiotensin-converting enzyme (ACE) inhibitor. The study is based on the results of the HOPE (Heart Outcomes Prevention Evaluation) study, a large international multicenter clinical trial (n = 9297). 2 Although economic data were not collected during the 4-year trial, Carroll et al. applied hospitalization costs related to differences in study endpoints between patients assigned to the placebo versus ramipril treatment arms. The results indicate that the use of this drug in this patient population is cost-justified.
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The purpose of this editorial is to describe precautions in reporting and interpreting economic assessments of clinical trials, particularly those in which economic data were not collected.
Application of Results Beyond Study Patients
There is the potential to apply the findings from clinical trials to patients beyond those included in the study. 3 Clinical trials are designed to increase the likelihood that a treatment effect will be identified. Thus, inclusion/exclusion criteria are specified such that patient enrollment is restricted to those who are most likely to be impacted by the treatment. In the HOPE study, patients at high risk for cardiovascular events (evidence of vascular disease or diabetes plus 1 other cardiovascular risk factor) were enrolled, excluding patients with heart failure or low (<0.40) ejection fraction. 2 The American Heart Association and the American College of Cardiology (AHA/ACC) guidelines include the use of ACE inhibitors as secondary prevention for all patients with coronary or other vascular disease, unless contraindicated. 4 Since Carroll et al. demonstrated noteworthy savings, practitioners might apply the results to patients with lower levels of risk for cardiac events or for primary prevention. However, economic implications for treating patient groups beyond the HOPE study population remain uncertain. Essentially, this involves the efficacy versus effectiveness controversy surrounding most clinical trials. As with the clinical findings, after publication, economic results are often applied beyond the study sample. However, the clinical and pharmacoeconomic impact may not be generalizable to a more diverse population.
Another consideration is race and ethnicity of the study population. The HOPE trial was conducted within 19 countries, across 3 continents. Thus, the population was diverse. Data regarding ethnicity, race, or numbers of patients randomized by country were not reported in the main trial publication. Since risk of cardiovascular disease and its outcomes have been shown to vary by ethnicity and race, it is unclear whether the results were impacted by these variables. Practice patterns also vary between countries, depending on the availability of resources and standards of care. For example, hospitalization rates may be higher in a particular country, and it is unclear whether this may have impacted these pharmacoeconomic results. Other demographic and treatment variables were reported in the primary trial publication. 2
LIMITATIONS OF THE ECONOMIC PERSPECTIVE
Another consideration is limitation of the economic perspective that can be applied from clinical trial results. The Panel on Cost-Effectiveness in Health and Medicine recommends that the base case economic analysis be conducted from the societal perspective. 5 As Carroll et al. specify, only hospitalization and study drug costs were included; therefore, the economic results provide a partial health-payer perspective. The results likely underestimate savings because societal costs associated with cardiovascular events (e.g., days of lost productivity, lost wages, disability) were not measured in the main clinical trial. However, a substudy of the HOPE conducted in Sweden did measure indirect costs and savings associated with the treatment. 6 We note that imputing indirect costs associated with the cardiovascular events in the HOPE trial would have been controversial. Practice patterns and, thus, healthcare costs would vary between countries in this international study. 7 Furthermore, estimations of social costs associated with lost productivity would be unique to the country of enrollment as well as the level of disability of these high-risk patients. Failure to incorporate the societal perspective does not diminish the importance of the results. However, if the clinical benefits were associated with increased direct medical costs, the societal perspective might be needed to compare the results with those of other healthcare interventions.
Measurement of Healthcare Costs
The limited costs reported by Carroll et al. suggest another precaution. Other healthcare utilization may have occurred as a result of the treatment. For example, there may be costs associated with adverse events from the treatment, which may have included inpatient care, outpatient visits, and/or drug treatment. The HOPE trial and economic analysis did incorporate the impact of noncompliance, drug discontinuance, and ACE inhibitor treatment among the placebo group. 2 Furthermore, underlying this pharmacoeconomic analysis is the assumption that all of the cardiovascular events avoided would occur among patients in the US, since US hospitalization costs were applied. As noted above, practice patterns and demographic variables unique to each country may have influenced the patterns of hospitalizations and outcomes associated with cardiovascular events. These could translate into dissimilar treatment costs.
Protocol-driven costs are sometimes a source of concern in economic analyses conducted in conjunction with clinical trials. 7,8 These costs may not occur in usual practice. Utilization data were not collected during the HOPE trial; therefore, it is not possible to gauge the potential impact of protocol-driven costs. We also note that the use of the consumer price index (CPI) to inflate costs to current dollars may have underestimated the economic gain associated with hospitalizations avoided. Generally, the CPI for medical care has outpaced the CPI for other goods and services. 9,10
Treatment Outcomes
Recently, there has been increased emphasis placed upon incorporating uniform outcome measures in economic analyses. Specifically, quality-adjusted life years (QALYs) are recommended for reference cases. 7,11, 12 Carroll et al. suggest an economic benefit from ramipril in terms of hospitalization costs alone. However, if results had been less favorable or the additional clinical benefits had been associated with additional overall costs, incorporation of a QALY outcome measure would have been helpful, or perhaps necessary, to allow comparisons with other healthcare interventions. 13 Health-related quality of life does not appear to have been assessed in the HOPE study. 2 Furthermore, mortality was not included or discussed by Carroll et al.
Consideration of a Class Effect
As Carroll et al. indicate in their sensitivity analysis, increasing the drug costs by 20% results in a break-even economic result. Although the HOPE trial results are specific to ramipril, it may be reasonable to assume that other ACE inhibitors would have similar benefit. Since Carroll et al. indicated that other ACE inhibitors have shown similar effects in clinical trials, it would be helpful to consider other ACE inhibitors in the sensitivity analysis. Assuming similar rates of cardiovascular events avoided, lower-cost ACE inhibitors could result in more favorable pharmacoeconomic results. Other drug-and patient-specific factors such as adverse effects could impact compliance and, thus, clinical and economic results. Current AHA/ACC recommendations include use of an ACE inhibitor after myocardial infarction. 4,14
Need for Economic-Clinical Trials
Randomized economic-clinical trials have inherent complexities and tend to be costly. Their results can have broad policy implications. 7,11, 15 The methodology must provide results that are generalizable regarding patient selection and assessment of treatment alternatives. The goal of these trials is to move toward an assessment of effectiveness, in contrast to clinical efficacy assessed in the contrived setting of controlled clinical trials. Healthcare costs tend to be skewed, with a small number of patients having high costs and the majority having much lower costs. Therefore, large sample sizes may be required to achieve sufficient statistical power to detect differences in costs as well as efficacy. 11 Furthermore, data collection is more extensive, including costs for medical and nonmedical resources and humanistic outcomes, such as health-related quality of life and patient preference measures. 16 There is debate regarding whether statistical testing of economic outcomes needs to be as rigorous as for clinical outcomes. It has been suggested that α levels >0.05 or 1-way statistical tests may be sufficient for pharmacoeconomic decision making. 11 We recognize the importance of post hoc reporting of the economic impact of large multicenter clinical trials even when economic data were not directly collected in conjunction with them. However, the above precautions should be considered. The publication of economic results extrapolated from a clinical trial does not preclude the need for economic studies alongside clinical trials or the need for separate trials with primarily pharmacoeconomic objectives.
The validity of post hoc and clinical economic studies has been compared. 11 In Table 1 , we summarize these concerns along with some additional considerations. We present some concepts that may be helpful in selecting the appropriate type of analysis and/or in evaluating the results of pharmacoeconomic research. We also assess the appropriateness of the use of post hoc economic analysis of the HOPE trial.
Summary
Pharmacoeconomic analyses imputed from clinical outcome data from large multicenter clinical trials provide a piece of the overall picture of the pharmacoeconomic impact of a specific therapy. The precautions that we outlined and the considerations listed in Table 1 can help interpret post hoc pharmacoeconomic analyses. Thus, additional research is needed to complete the pharmacoeconomic description of the impact of ACE inhibitors in cardiovascular disease. 11 differences in practice patterns not discussed Inclusion/exclusion broad inclusion criteria, diverse inclusion/exclusion criteria restrict few exclusion criteria; most applicable criteria 11 study population study to selected patients and patients eligible for treatment providers Importance of economic unproven intervention or 1 with economic claims necessary for new indication for this drug class, claims for adoption few alternatives application of results but other ACE inhibitors available and could have been included in sensitivity analysis
Relative cost of inter-low cost/pt., limited high cost/pt., potential for low cost/pt., but broad application vention and potential for application and impact across broad application and large and potential for large economic application throughout healthcare system economic impact on impact healthcare system healthcare system
Complexity of intervention minimal complexity to implement complex interventions, implemented low level of complexity, low potential for at organizational level adverse impact from drug ACE = angiotensin-converting enzyme; HOPE = Heart Outcomes Prevention Evaluation.
